IN VITRO SCREENING OF CHEMOPREVENTIVE AGENTS

化学预防剂的体外筛选

• 批准号: 2834300
• 负责人: SHEELA SHARMA
• 金额: $ 23.24万
• 依托单位: ALION SCIENCE AND TECHNOLOGY CORP
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2834300
• 关键词: angiogenesis; angiogenesis inhibitors; aorta; cancer prevention; carcinogenesis inhibitor; chemoprevention; chick embryo; chorioallantoic membrane; drug screening /evaluation; laboratory rat; tissue /cell culture; vascular endothelium

Angiogenesis is the growth of new blood vessels from existing ones. It is an important aspect of new tissue development, tissue growth, and tissue repair. It is also a component of many diseases, including cancer. Angiogenesis is necessary for the growth of tumors and their metastasis. The induction of Angiogenesis is mediated by angiogenic growth factors produced by either tumor or host cells. Chemopreventive, agents which inhibit or retard Angiogenesis are urgently needed. The purpose of this project is to screen selected chemopreventive agents for antiangiogenic activity in vitro. A main concern in the development of antiangiogenic therapies is the availability of sensitive and specific disease models. The present project focuses on the utilization of in vitro assay systems that can be used to screen antiangiogenic drugs. These in vitro assay systems include but are not limited to 1) chorioallantoic membrane in shelled or shelled - less chick embryos, 2) explants of rat aorta embedded in collagen gel grown in serum - free media, and 3) Microvascular endothelial cell culture. The contractor is using the most sensitive system of their choice, wherein the effects of the antiangiogenic factors are quantitated. For each agent, the system of choice shall be first calibrated in the presence of a well defined angiogenic factor as a positive control and in the absence of such factor as a negative control. The system of choice includes the presence of human tumor cells as a positive control.

血管生成是从现有血管生长出新血管。 它是新组织发育、组织生长的一个重要方面， 和组织修复。它也是许多疾病的组成部分，包括 癌症。血管生成对于肿瘤及其生长是必需的 转移。血管生成的诱导是由血管生成介导的 由肿瘤或宿主细胞产生的生长因子。 化学预防，抑制或延缓血管生成的药物是 急需。该项目的目的是筛选选定的 体外抗血管生成活性的化学预防剂。一个主要 抗血管生成疗法的发展令人担忧的是 敏感和特定疾病模型的可用性。现在的 项目重点是利用体外测定系统 可用于筛选抗血管生成药物。这些体外测定 系统包括但不限于1)绒毛尿囊膜 在去壳或去壳-少鸡胚胎中，2) 大鼠主动脉外植体 嵌入在无血清培养基中生长的胶原凝胶中，以及3) 微血管内皮细胞培养。承包商正在使用 他们选择的最敏感的系统，其中的影响 抗血管生成因子被定量。对于每个代理，系统 选择应首先在存在明确定义的情况下进行校准 血管生成因子作为阳性对照，并且在没有这样的情况下 因子作为阴性对照。 选择的系统包括 人类肿瘤细胞的存在作为阳性对照。